Skip to content
OpenCapital
Get started

Arcutis Biotherapeutics, Inc. ARQT Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
——
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
——

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.29B+57.5%

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number?
Arcutis Biotherapeutics, Inc. (ARQT) reported share-based compensation arrangement by share-based payment award, options, outstanding, number of $7.6M in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number changed year-over-year?
Arcutis Biotherapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number increased by 9.2% year-over-year, from $6.96M to $7.6M.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number?
Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number has grown at a 12.0% compound annual growth rate (CAGR), from $3.66M to $6.44M.